ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Last Price$238.0(1.1%)
Market Cap$30.1B
LTM Net Income
($332.3M)
YoY Growth
-34.8%
3Y CAGR
-26.5%
5Y CAGR
-16.6%
Stock quality & Intrinsic value
6/10
64.3% overvalued

Alnylam Pharmaceuticals, Inc. Net Income

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Net Income
($32.7M)
($42.9M)
($34.6M)
($85.5M)
($26.2M)
($47.6M)
($43.5M)
($57.6M)
($106.0M)
($89.2M)
($360.4M)
($290.1M)
($410.1M)
($490.9M)
($761.5M)
($886.1M)
($858.3M)
($852.8M)
($1,131.2M)
($440.2M)
ALNY
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for ALNY and see if it's the right time to invest.
Dive in

Alnylam Pharmaceuticals, Inc. (ALNY) Net Income comparison analysis

Crunching data... Almost there!

ALNY key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is Alnylam Pharmaceuticals, Inc.'s Net Income?

As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month Net Income is ($332.3M), based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is Alnylam Pharmaceuticals, Inc.'s Net Income growth rate?

Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Income growth was (34.8%). The average annual Net Income growth rates for Alnylam Pharmaceuticals, Inc. have been (27.6%) over the past three years, (16.6%) over the past five years.

3) Is Alnylam Pharmaceuticals, Inc.'s Net Income growth rate Good?

Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Income growth was (34.8%), which is lower than industry growth of (0.1%). It indicates that Alnylam Pharmaceuticals, Inc.'s Net Income growth is Bad.